AAPL299.77+1.76 (+0.59%) ▲|ABBV230.63+14.14 (+6.53%) ▲|ABT87.83-0.59 (-0.66%) ▼|ACN121.53-6.45 (-5.04%) ▼|ADBE193.54-1.63 (-0.83%) ▼|AMAT627.06+9.95 (+1.61%) ▲|AMD546.40+9.03 (+1.68%) ▲|AMGN342.18+4.58 (+1.36%) ▲|AMT177.24+1.19 (+0.68%) ▲|AMZN233.57-10.82 (-4.43%) ▼|AVGO394.92-16.43 (-3.99%) ▼|AXP337.15-0.86 (-0.25%) ▼|BA221.59-1.13 (-0.51%) ▼|BAC57.41+1.21 (+2.14%) ▲|BKNG165.27-6.51 (-3.79%) ▼|BLK1,050.06-0.03 (0.00%) ▼|BMY54.35+0.35 (+0.64%) ▲|BNY145.88+2.25 (+1.56%) ▲|BRK-B490.10+0.64 (+0.13%) ▲|C145.74+2.68 (+1.87%) ▲|CAT1,016.41+30.59 (+3.10%) ▲|CL90.52+1.04 (+1.16%) ▲|CMCSA22.41-0.03 (-0.11%) ▼|COF199.29-2.24 (-1.11%) ▼|COP109.01+1.27 (+1.18%) ▲|COST950.35-1.10 (-0.12%) ▼|CRM149.09-2.69 (-1.77%) ▼|CSCO121.05+1.51 (+1.26%) ▲|CVS102.59+4.27 (+4.34%) ▲|CVX173.80+0.17 (+0.10%) ▲|DE603.46+14.22 (+2.41%) ▲|DHR175.83-1.34 (-0.76%) ▼|DIS102.88-1.01 (-0.97%) ▼|DUK124.52+0.66 (+0.53%) ▲|EMR150.68+0.02 (+0.01%) ▲|FDX329.82+4.84 (+1.49%) ▲|GD345.22-4.79 (-1.37%) ▼|GE357.640.00 (0.00%) ▼|GEV1,114.95+5.22 (+0.47%) ▲|GILD123.82+0.06 (+0.05%) ▲|GM82.58+3.29 (+4.15%) ▲|GOOG342.22-25.24 (-6.87%) ▼|GOOGL342.77-25.26 (-6.86%) ▼|GS1,094.90-1.66 (-0.15%) ▼|HD329.78-4.50 (-1.35%) ▼|HON231.08+2.07 (+0.90%) ▲|IBM246.19-2.92 (-1.17%) ▼|INTC140.02+6.03 (+4.50%) ▲|INTU258.80-8.20 (-3.07%) ▼|ISRG401.85-4.94 (-1.21%) ▼|JNJ230.89+2.50 (+1.09%) ▲|JPM330.36+5.14 (+1.58%) ▲|KO79.54+0.15 (+0.18%) ▲|LIN512.40+0.25 (+0.05%) ▲|LLY1,098.30-0.27 (-0.02%) ▼|LMT495.22-15.73 (-3.08%) ▼|LOW216.04-6.16 (-2.77%) ▼|LRCX394.19+5.15 (+1.32%) ▲|MA487.65-2.14 (-0.44%) ▼|MCD274.12-4.49 (-1.61%) ▼|MDLZ60.06-0.06 (-0.10%) ▼|MDT78.90-0.44 (-0.55%) ▼|META561.37-15.85 (-2.75%) ▼|MMM162.94+2.34 (+1.45%) ▲|MO69.98+0.86 (+1.24%) ▲|MRK113.73-0.15 (-0.13%) ▼|MS226.88+3.71 (+1.66%) ▲|MSFT371.46-7.94 (-2.09%) ▼|MU1,191.02+57.03 (+5.03%) ▲|NEE87.21+0.46 (+0.53%) ▲|NFLX74.12-3.26 (-4.22%) ▼|NKE43.52-1.68 (-3.72%) ▼|NOW93.18-1.86 (-1.96%) ▼|NVDA209.31-1.38 (-0.66%) ▼|ORCL178.82-5.47 (-2.97%) ▼|PEP141.71-0.31 (-0.22%) ▼|PFE25.11-0.10 (-0.38%) ▼|PG150.08-0.31 (-0.20%) ▼|PLTR122.33-6.14 (-4.78%) ▼|PM175.39-3.01 (-1.69%) ▼|QCOM228.57+2.46 (+1.09%) ▲|RTX181.93-3.67 (-1.98%) ▼|SBUX100.87+0.22 (+0.21%) ▲|SCHW91.86+0.16 (+0.17%) ▲|SO93.80+0.71 (+0.76%) ▲|SPG213.77+2.44 (+1.15%) ▲|T22.37+0.36 (+1.64%) ▲|TMO459.70-4.92 (-1.06%) ▼|TMUS180.80-0.87 (-0.48%) ▼|TSLA408.50+8.01 (+2.00%) ▲|TXN332.07+9.21 (+2.85%) ▲|UBER71.77+0.13 (+0.17%) ▲|UNH405.93+4.97 (+1.24%) ▲|UNP261.35+4.47 (+1.74%) ▲|UPS107.99+3.13 (+2.98%) ▲|USB58.85+0.71 (+1.21%) ▲|V330.32+3.08 (+0.94%) ▲|VZ45.65+0.28 (+0.62%) ▲|WFC83.42+1.22 (+1.48%) ▲|WMT117.70+0.52 (+0.44%) ▲|XOM137.76-0.05 (-0.04%) ▼|AAPL299.77+1.76 (+0.59%) ▲|ABBV230.63+14.14 (+6.53%) ▲|ABT87.83-0.59 (-0.66%) ▼|ACN121.53-6.45 (-5.04%) ▼|ADBE193.54-1.63 (-0.83%) ▼|AMAT627.06+9.95 (+1.61%) ▲|AMD546.40+9.03 (+1.68%) ▲|AMGN342.18+4.58 (+1.36%) ▲|AMT177.24+1.19 (+0.68%) ▲|AMZN233.57-10.82 (-4.43%) ▼|AVGO394.92-16.43 (-3.99%) ▼|AXP337.15-0.86 (-0.25%) ▼|BA221.59-1.13 (-0.51%) ▼|BAC57.41+1.21 (+2.14%) ▲|BKNG165.27-6.51 (-3.79%) ▼|BLK1,050.06-0.03 (0.00%) ▼|BMY54.35+0.35 (+0.64%) ▲|BNY145.88+2.25 (+1.56%) ▲|BRK-B490.10+0.64 (+0.13%) ▲|C145.74+2.68 (+1.87%) ▲|CAT1,016.41+30.59 (+3.10%) ▲|CL90.52+1.04 (+1.16%) ▲|CMCSA22.41-0.03 (-0.11%) ▼|COF199.29-2.24 (-1.11%) ▼|COP109.01+1.27 (+1.18%) ▲|COST950.35-1.10 (-0.12%) ▼|CRM149.09-2.69 (-1.77%) ▼|CSCO121.05+1.51 (+1.26%) ▲|CVS102.59+4.27 (+4.34%) ▲|CVX173.80+0.17 (+0.10%) ▲|DE603.46+14.22 (+2.41%) ▲|DHR175.83-1.34 (-0.76%) ▼|DIS102.88-1.01 (-0.97%) ▼|DUK124.52+0.66 (+0.53%) ▲|EMR150.68+0.02 (+0.01%) ▲|FDX329.82+4.84 (+1.49%) ▲|GD345.22-4.79 (-1.37%) ▼|GE357.640.00 (0.00%) ▼|GEV1,114.95+5.22 (+0.47%) ▲|GILD123.82+0.06 (+0.05%) ▲|GM82.58+3.29 (+4.15%) ▲|GOOG342.22-25.24 (-6.87%) ▼|GOOGL342.77-25.26 (-6.86%) ▼|GS1,094.90-1.66 (-0.15%) ▼|HD329.78-4.50 (-1.35%) ▼|HON231.08+2.07 (+0.90%) ▲|IBM246.19-2.92 (-1.17%) ▼|INTC140.02+6.03 (+4.50%) ▲|INTU258.80-8.20 (-3.07%) ▼|ISRG401.85-4.94 (-1.21%) ▼|JNJ230.89+2.50 (+1.09%) ▲|JPM330.36+5.14 (+1.58%) ▲|KO79.54+0.15 (+0.18%) ▲|LIN512.40+0.25 (+0.05%) ▲|LLY1,098.30-0.27 (-0.02%) ▼|LMT495.22-15.73 (-3.08%) ▼|LOW216.04-6.16 (-2.77%) ▼|LRCX394.19+5.15 (+1.32%) ▲|MA487.65-2.14 (-0.44%) ▼|MCD274.12-4.49 (-1.61%) ▼|MDLZ60.06-0.06 (-0.10%) ▼|MDT78.90-0.44 (-0.55%) ▼|META561.37-15.85 (-2.75%) ▼|MMM162.94+2.34 (+1.45%) ▲|MO69.98+0.86 (+1.24%) ▲|MRK113.73-0.15 (-0.13%) ▼|MS226.88+3.71 (+1.66%) ▲|MSFT371.46-7.94 (-2.09%) ▼|MU1,191.02+57.03 (+5.03%) ▲|NEE87.21+0.46 (+0.53%) ▲|NFLX74.12-3.26 (-4.22%) ▼|NKE43.52-1.68 (-3.72%) ▼|NOW93.18-1.86 (-1.96%) ▼|NVDA209.31-1.38 (-0.66%) ▼|ORCL178.82-5.47 (-2.97%) ▼|PEP141.71-0.31 (-0.22%) ▼|PFE25.11-0.10 (-0.38%) ▼|PG150.08-0.31 (-0.20%) ▼|PLTR122.33-6.14 (-4.78%) ▼|PM175.39-3.01 (-1.69%) ▼|QCOM228.57+2.46 (+1.09%) ▲|RTX181.93-3.67 (-1.98%) ▼|SBUX100.87+0.22 (+0.21%) ▲|SCHW91.86+0.16 (+0.17%) ▲|SO93.80+0.71 (+0.76%) ▲|SPG213.77+2.44 (+1.15%) ▲|T22.37+0.36 (+1.64%) ▲|TMO459.70-4.92 (-1.06%) ▼|TMUS180.80-0.87 (-0.48%) ▼|TSLA408.50+8.01 (+2.00%) ▲|TXN332.07+9.21 (+2.85%) ▲|UBER71.77+0.13 (+0.17%) ▲|UNH405.93+4.97 (+1.24%) ▲|UNP261.35+4.47 (+1.74%) ▲|UPS107.99+3.13 (+2.98%) ▲|USB58.85+0.71 (+1.21%) ▲|V330.32+3.08 (+0.94%) ▲|VZ45.65+0.28 (+0.62%) ▲|WFC83.42+1.22 (+1.48%) ▲|WMT117.70+0.52 (+0.44%) ▲|XOM137.76-0.05 (-0.04%) ▼|
22.8 C
New York
Monday, June 22, 2026

Tag: treatments

newssourceFORcompanyinformationcontent1marketreleases

uniQure to Announce Second Quarter 2025 Financial Results

uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET 
uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET

Lecanemab four-year efficacy and safety data to be presented at AAIC 2025

STOCKHOLM, July 22, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®), including...

Precision Era to Redefine Treatment, Drive $450B Economic Investment and Change Lives Across Asia Pacific

SINGAPORE, July 22, 2025 /PRNewswire/ -- The Precision Era of medicine is arriving in Asia Pacific, driven by the arrival of a critical mass...

Neuraxpharm continues international expansion with launch of Neuraxpharm Australia

Avendran Naidu appointed Head of Commercial to lead new affiliate CNS specialist continues growth strategy outside Europe to commercialise CNS treatments, including Nuvigil® (armodafinil), Modavigil®...

Neuraxpharm continues international expansion with launch of Neuraxpharm Australia

Avendran Naidu appointed Head of Commercial to lead new affiliate CNS specialist continues growth strategy outside Europe to commercialise CNS treatments, including Nuvigil® (armodafinil), Modavigil®...

EISAI TO PRESENT FOUR-YEAR EFFICACY AND SAFETY DATA ON CONTINUOUS TREATMENT WITH LECANEMAB AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025

Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid,...

Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer’s Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau.

NakedMD, Inc. Announces New Location in Walnut Creek, CA

New studio at 240 La Casa Via continues NakedMD's mission of providing innovative, personalized care WALNUT CREEK, Calif., July 21, 2025 /PRNewswire/ -- NakedMD, Inc....

Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight

The interleukin-17 inhibitors market is expected to remain strong in rheumatology (psoriasis and arthritis), with potential expansion into hidradenitis suppurativa and other dermatologic conditions....

Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight

The interleukin-17 inhibitors market is expected to remain strong in rheumatology (psoriasis and arthritis), with potential expansion into hidradenitis suppurativa and other dermatologic conditions....

Summer Pitch: How to Prevent Baseball Injuries This Season

The American Academy of Orthopaedic Surgeons share expert tips to help players stay safe on the field ROSEMONT, Ill., July 21, 2025 /PRNewswire/ -- Baseball...

Marriott International Caribbean Highlights the Unmatched Appeal of Summer Travel Across Its Premier Resorts

Discover exceptional value, vibrant culture, and serene waters this summer at Marriott's leading Caribbean destinations PLANTATION, Fla., July 21, 2025 /PRNewswire/ -- Marriott International's Caribbean...

Autonomix Medical, Inc. Granted New U.S. Patent to Advance Minimally Invasive, Nerve-Focused Treatments Across High-Need Indications

With over 80 issued patents and 40 pending patent applications, Autonomix is building a comprehensive IP portfolio in nerve-sensing and modulation, strengthening its strategic position in a multi-billion-dollar market opportunity and unlocking potential across cardiovascular, renal, and other high-burden diseases

CLL Society Awards Research Projects Advancing CLL/SLL Care

2025 Research Program supports innovative studies aimed at improving outcomes and quality of life for CLL and SLL patients SAN DIEGO, July 21, 2025 /PRNewswire/...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTreatments

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers